JP2021513329A5 - - Google Patents

Info

Publication number
JP2021513329A5
JP2021513329A5 JP2020541805A JP2020541805A JP2021513329A5 JP 2021513329 A5 JP2021513329 A5 JP 2021513329A5 JP 2020541805 A JP2020541805 A JP 2020541805A JP 2020541805 A JP2020541805 A JP 2020541805A JP 2021513329 A5 JP2021513329 A5 JP 2021513329A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513329A (ja
JP7268038B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016156 external-priority patent/WO2019152715A1/en
Publication of JP2021513329A publication Critical patent/JP2021513329A/ja
Publication of JP2021513329A5 publication Critical patent/JP2021513329A5/ja
Priority to JP2023068910A priority Critical patent/JP7486636B2/ja
Application granted granted Critical
Publication of JP7268038B2 publication Critical patent/JP7268038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541805A 2018-01-31 2019-01-31 抗ms4a4a抗体及びその使用方法 Active JP7268038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023068910A JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ms4a4a抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624600P 2018-01-31 2018-01-31
US62/624,600 2018-01-31
US201862783096P 2018-12-20 2018-12-20
US62/783,096 2018-12-20
PCT/US2019/016156 WO2019152715A1 (en) 2018-01-31 2019-01-31 Anti-ms4a4a antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023068910A Division JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ms4a4a抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021513329A JP2021513329A (ja) 2021-05-27
JP2021513329A5 true JP2021513329A5 (enExample) 2022-02-07
JP7268038B2 JP7268038B2 (ja) 2023-05-02

Family

ID=65444352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541805A Active JP7268038B2 (ja) 2018-01-31 2019-01-31 抗ms4a4a抗体及びその使用方法
JP2023068910A Active JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ms4a4a抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023068910A Active JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ms4a4a抗体及びその使用方法

Country Status (5)

Country Link
US (3) US11472874B2 (enExample)
EP (1) EP3746476A1 (enExample)
JP (2) JP7268038B2 (enExample)
CN (1) CN111971301B (enExample)
WO (1) WO2019152715A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019152706A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
CA3145885A1 (en) 2019-07-31 2021-02-04 Jeonghoon Sun Anti-ms4a4a antibodies and methods of use thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
JP2025503437A (ja) 2021-12-17 2025-02-04 デナリ セラピューティクス インコーポレイテッド ポリペプチド操作、ライブラリー、ならびに操作されたcd98重鎖及びトランスフェリン受容体結合ポリペプチド
EP4455275A4 (en) * 2021-12-22 2026-03-18 Univ Kagoshima MACROPHAGE PRODUCTION METHOD, DIFFERENCE-INDUCING AGENT, DIFFERENCE-INDUCING KIT, MACROPHAGE CULTIVATION METHOD, MACROPHAGE PROPAGATION-PROMOTING AGENT, MACROPHAGE PROLIFERATION-PROMOTING KIT, MACROPHAGE PROLIFERATION METHOD, AND MACROPHAGES
EP4562184A2 (en) * 2022-07-29 2025-06-04 Anavex Life Sciences Corp. Therapy selection and treatment of neurodegenerative disorders
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN115850460B (zh) * 2022-11-21 2025-10-17 浙江大学医学院附属第一医院 抗y系乙型流感病毒血凝素蛋白单克隆抗体2h6及其在检测中的应用
CN116789821A (zh) * 2022-12-07 2023-09-22 南方医科大学南方医院 Ms4a4a作为靶点或抗ms4a4a单克隆抗体在制备治疗结直肠癌的药物中的应用
JPWO2024262577A1 (enExample) * 2023-06-21 2024-12-26
WO2025049981A1 (en) * 2023-09-01 2025-03-06 Institute For Environmental Health, Inc. Variably deamidated gluten polypeptides and antibodies against same
WO2025096087A1 (en) 2023-10-30 2025-05-08 Regeneron Pharmaceuticals, Inc. Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors
CN119431583B (zh) * 2024-12-19 2025-09-30 重庆国际免疫创新中心有限公司 靶向cd155的抗体或抗原结合片段及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
AU2002251692A1 (en) * 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
GB0125338D0 (en) 2001-10-22 2001-12-12 Isis Innovation Process for reducing immunogenic reactions using selective TH1 cell binding antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
GB0324888D0 (en) 2003-10-24 2003-11-26 Novartis Ag Organic compounds
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP2008506637A (ja) 2004-06-14 2008-03-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 胎児起源の細胞に対する抗体
CN101001879A (zh) 2004-06-14 2007-07-18 伊利诺伊大学董事会 与胎儿而非成体cd34+/cd36+细胞结合的抗体
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
EP2390349A1 (en) 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
NO2748201T3 (enExample) 2011-08-23 2018-05-12
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20190321443A1 (en) 2016-02-16 2019-10-24 President And Fellows Of Harvard College Modulators of MS4A activity
CN105759057A (zh) * 2016-04-12 2016-07-13 上海凯璟生物科技有限公司 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法
CN105969901B (zh) 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2019152706A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
MA54880A (fr) 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
CA3145885A1 (en) 2019-07-31 2021-02-04 Jeonghoon Sun Anti-ms4a4a antibodies and methods of use thereof
KR20220084095A (ko) 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies

Similar Documents

Publication Publication Date Title
JP2021513329A5 (enExample)
JP2022542964A5 (enExample)
HRP20230675T1 (hr) Anti-trem2 protutijela i postupci njihove uporabe
JP7323513B2 (ja) 抗4-1bb抗体とその作製及び使用方法
JP2020533948A5 (enExample)
JP2020532947A5 (enExample)
JP2021513328A5 (enExample)
JP2017523814A5 (enExample)
CN111670203B (zh) 双特异性抗体
JP7476997B2 (ja) 二重特異性抗体
JP2021530960A5 (enExample)
JP2019519492A5 (enExample)
JP2021531027A5 (enExample)
JP7688805B2 (ja) 二重特異性抗体
IL304898A (en) New anti-CD24 antibodies
JP2021526794A5 (enExample)
JP7574692B2 (ja) 二重特異性抗体
JP2022537279A (ja) α-syn/IGF1Rに対する二重特異抗体およびその用途
JP2024541476A5 (enExample)
JP7641292B2 (ja) 抗cd19抗体、その使用方法及び製造方法
JP7714992B2 (ja) 二重特異性抗体を有効成分として含む医薬組成物
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof
WO2024167877A2 (en) Anti-muc16 antibodies
NZ758448B2 (en) Anti-sortilin antibodies and methods of use thereof
NZ758448A (en) Anti-sortilin antibodies and methods of use thereof